$38.60
Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene: Q2 Earnings Snapshot
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Overview
52-week range
$16
$44
82% of range
Avg surprise (last 3)
+1.0%
Avg reaction (last 2)
+0.2%
50% positive
Latest IV / EM
119%
EM ±18.7% · $40 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.53 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-1.39 | $-1.35 | -3.0% | -28.7% | +2.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.99 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-1.05 | $-1.15 | +8.7% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-1.08 | $-1.05 | -2.9% | — | -1.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.19 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.09 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.00 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-32.67 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-26.68 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.26 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-37M | $-33M | — | $-24M | $-26M | $-26M | — | $-22M |
| Net income | $-34M | $-31M | — | $-21M | $-22M | $-23M | — | $-20M |
| EPS (diluted) | $-1.53 | $-1.39 | — | $-0.99 | $-1.05 | $-1.08 | — | $-1.19 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $112M | $124M | $104M | $71M | $59M | $71M | $137M | $67M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $229M | $247M | $272M | $271M | $279M | $296M | $316M | $144M |
| Total assets | $244M | $263M | $289M | $288M | $297M | $315M | $336M | $164M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $27M | $25M | $24M | $22M | $24M | $24M | $25M | $27M |
| Total equity | $217M | $238M | $265M | $266M | $273M | $292M | $310M | $137M |